Immix Biopharma, Inc. reported a net loss of $10.1 million for the first quarter of 2026, a significant increase from the $4.5 million loss recorded in the same period of 2025. The company's total operating expenses surged to $10.8 million, up from $4.7 million year-over-year, primarily driven by a rise in research and development costs, which reached $6.0 million compared to $2.0 million in the prior year. General and administrative expenses also increased to $4.8 million, reflecting higher investor relations and professional fees as the company continues to pursue capital raising efforts.

The company's financial position showed a decline in cash and cash equivalents, which fell to approximately $79.3 million as of March 31, 2026, down from $93.9 million at the end of 2025. This decrease was attributed to the net loss and cash used in operating activities, which amounted to $9.8 million for the quarter. Immix Biopharma's total assets were reported at $95.8 million, with total liabilities of $11.5 million, resulting in stockholders' equity of $84.4 million.

Strategically, Immix Biopharma is focused on advancing its lead candidate, NXC-201, a chimeric antigen receptor T-cell therapy for the treatment of relapsed/refractory AL Amyloidosis. The company is currently conducting a Phase 1b/2 clinical trial in the U.S. and has received Breakthrough Therapy designation from the FDA for this candidate. Additionally, the company has been awarded an $8.0 million grant from the California Institute for Regenerative Medicine to support the clinical development of NXC-201, with $1.5 million received in reimbursements during the first quarter of 2026.

Operationally, Immix Biopharma has made significant strides in its clinical programs, with the NEXICART-2 trial expected to enroll 40 patients. The company reported that 75% of patients in the trial achieved complete responses, indicating promising efficacy for NXC-201. As of March 31, 2026, the company had approximately 55.4 million shares outstanding, reflecting a slight increase in share count due to stock option exercises and other equity transactions. Looking ahead, Immix Biopharma anticipates continued investment in its clinical trials and research activities, with plans to seek additional funding to support its operations and growth initiatives.

About Immix Biopharma, Inc.

Immix Biopharma is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR-T, for light chain (AL) Amyloidosis and immune-mediated diseases. Its lead candidate, NXC-201, targets relapsed/refractory AL Amyloidosis, with ongoing clinical trials and regulatory designations including Orphan Drug and RMAT. The company focuses on leveraging proprietary platforms to create accessible, targeted treatments for serious, underserved conditions.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.